Trials / Not Yet Recruiting
Not Yet RecruitingNCT07092449
Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma
Pucotenlimab Combined With Chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin) in the Perioperative Treatment of Locally Advanced Gastroesophageal Junction Tumors, A Multi-center Prospective Study
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Tang-Du Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, multicenter, single-arm clinical trial. The study intends to enroll patients with pathologically or cytologically confirmed resectable locally advanced gastroesophageal junction tumors (cT2N+M0 and cT3-4bNxM0) who have not received prior systemic therapy. After signing the informed consent and being screened to meet the inclusion and exclusion criteria, patients will receive 3 cycles of Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin). Preoperative imaging evaluations will be performed 3 to 6 weeks after the final dose administration to assess the efficacy of neoadjuvant therapy and the feasibility of radical resection. Efficacy evaluation will be performed after radical surgery for locally advanced gastroesophageal junction tumors.
Conditions
- Gastroesophageal Junction
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Neoadjuvant Chemoimmunotherapy
- Adjuvant Therapy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neoadjuvant chemo-immunotherapy | Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin) |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2025-07-29
- Last updated
- 2025-07-29
Source: ClinicalTrials.gov record NCT07092449. Inclusion in this directory is not an endorsement.